2
3
4
5
6
7 LONG TITLE
8 General Description:
9 This bill amends a provision related to controlled substances.
10 Highlighted Provisions:
11 This bill:
12 ▸ provides a schedule in the state Controlled Substances Act for cannabidiol in a drug
13 product approved by the United States Food and Drug Administration.
14 Money Appropriated in this Bill:
15 None
16 Other Special Clauses:
17 None
18 Utah Code Sections Affected:
19 AMENDS:
20 58-37-4, as last amended by Laws of Utah 2015, Chapter 258
21
22 Be it enacted by the Legislature of the state of Utah:
23 Section 1. Section 58-37-4 is amended to read:
24 58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings
25 required -- Specific substances included in schedules.
26 (1) There are established five schedules of controlled substances known as Schedules I,
27 II, III, IV, and V which consist of substances listed in this section.
28 (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
29 the official name, common or usual name, chemical name, or brand name designated:
30 (a) Schedule I:
31 (i) Unless specifically excepted or unless listed in another schedule, any of the
32 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
33 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
34 chemical designation:
35 (A) Acetyl-alpha-methylfentanyl
36 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
37 (B) Acetylmethadol;
38 (C) Allylprodine;
39 (D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
40 levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
41 (E) Alphameprodine;
42 (F) Alphamethadol;
43 (G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
44 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
45 (H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
46 piperidinyl]-N-phenylpropanamide);
47 (I) Benzylpiperazine;
48 (J) Benzethidine;
49 (K) Betacetylmethadol;
50 (L) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
51 piperidinyl]-N-phenylpropanamide);
52 (M) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
53 phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
54 (N) Betameprodine;
55 (O) Betamethadol;
56 (P) Betaprodine;
57 (Q) Clonitazene;
58 (R) Dextromoramide;
59 (S) Diampromide;
60 (T) Diethylthiambutene;
61 (U) Difenoxin;
62 (V) Dimenoxadol;
63 (W) Dimepheptanol;
64 (X) Dimethylthiambutene;
65 (Y) Dioxaphetyl butyrate;
66 (Z) Dipipanone;
67 (AA) Ethylmethylthiambutene;
68 (BB) Etonitazene;
69 (CC) Etoxeridine;
70 (DD) Furethidine;
71 (EE) Hydroxypethidine;
72 (FF) Ketobemidone;
73 (GG) Levomoramide;
74 (HH) Levophenacylmorphan;
75 (II) Morpheridine;
76 (JJ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
77 (KK) Noracymethadol;
78 (LL) Norlevorphanol;
79 (MM) Normethadone;
80 (NN) Norpipanone;
81 (OO) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
82 propanamide;
83 (PP) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
84 (QQ) Phenadoxone;
85 (RR) Phenampromide;
86 (SS) Phenomorphan;
87 (TT) Phenoperidine;
88 (UU) Piritramide;
89 (VV) Proheptazine;
90 (WW) Properidine;
91 (XX) Propiram;
92 (YY) Racemoramide;
93 (ZZ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
94 (AAA) Tilidine;
95 (BBB) Trimeperidine;
96 (CCC) 3-methylfentanyl, including the optical and geometric isomers
97 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
98 (DDD) 3-methylthiofentanyl
99 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
100 (ii) Unless specifically excepted or unless listed in another schedule, any of the
101 following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
102 salts, isomers, and salts of isomers is possible within the specific chemical designation:
103 (A) Acetorphine;
104 (B) Acetyldihydrocodeine;
105 (C) Benzylmorphine;
106 (D) Codeine methylbromide;
107 (E) Codeine-N-Oxide;
108 (F) Cyprenorphine;
109 (G) Desomorphine;
110 (H) Dihydromorphine;
111 (I) Drotebanol;
112 (J) Etorphine (except hydrochloride salt);
113 (K) Heroin;
114 (L) Hydromorphinol;
115 (M) Methyldesorphine;
116 (N) Methylhydromorphine;
117 (O) Morphine methylbromide;
118 (P) Morphine methylsulfonate;
119 (Q) Morphine-N-Oxide;
120 (R) Myrophine;
121 (S) Nicocodeine;
122 (T) Nicomorphine;
123 (U) Normorphine;
124 (V) Pholcodine; and
125 (W) Thebacon.
126 (iii) Unless specifically excepted or unless listed in another schedule, any material,
127 compound, mixture, or preparation which contains any quantity of the following hallucinogenic
128 substances, or which contains any of their salts, isomers, and salts of isomers when the
129 existence of the salts, isomers, and salts of isomers is possible within the specific chemical
130 designation; as used in this Subsection (2)(a)(iii) only, "isomer" includes the optical, position,
131 and geometric isomers:
132 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
133 α-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α-ET; and AET;
134 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
135 4-bromo-2,5-dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA;
136 (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:
137 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
138 (D) 2,5-dimethoxyamphetamine, some trade or other names:
139 2,5-dimethoxy-α-methylphenethylamine; 2,5-DMA;
140 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
141 (F) 4-methoxyamphetamine, some trade or other names:
142 4-methoxy-α-methylphenethylamine; paramethoxyamphetamine, PMA;
143 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
144 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
145 4-methyl-2,5-dimethoxy-α-methylphenethylamine; "DOM"; and "STP";
146 (I) 3,4-methylenedioxy amphetamine;
147 (J) 3,4-methylenedioxymethamphetamine (MDMA);
148 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
149 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
150 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
151 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
152 (M) 3,4,5-trimethoxy amphetamine;
153 (N) Bufotenine, some trade and other names:
154 3-(β-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
155 N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
156 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
157 (P) Dimethyltryptamine, some trade or other names: DMT;
158 (Q) Ibogaine, some trade and other names:
159 7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
160 [5,4-b] indole; Tabernanthe iboga;
161 (R) Lysergic acid diethylamide;
162 (S) Marijuana;
163 (T) Mescaline;
164 (U) Parahexyl, some trade or other names:
165 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
166 (V) Peyote, meaning all parts of the plant presently classified botanically as
167 Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
168 any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
169 preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
170 (W) N-ethyl-3-piperidyl benzilate;
171 (X) N-methyl-3-piperidyl benzilate;
172 (Y) Psilocybin;
173 (Z) Psilocyn;
174 (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis
175 (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
176 plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,
177 and their isomers with similar chemical structure and pharmacological activity to those
178 substances contained in the plant, such as the following: Δ1 cis or trans tetrahydrocannabinol,
179 and their optical isomers Δ6 cis or trans tetrahydrocannabinol, and their optical isomers Δ3,4
180 cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
181 substances is not internationally standardized, compounds of these structures, regardless of
182 numerical designation of atomic positions covered;
183 (BB) Ethylamine analog of phencyclidine, some trade or other names:
184 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
185 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
186 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
187 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
188 (DD) Thiophene analog of phencyclidine, some trade or other names:
189 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
190 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
191 (iv) Unless specifically excepted or unless listed in another schedule, any material
192 compound, mixture, or preparation which contains any quantity of the following substances
193 having a depressant effect on the central nervous system, including its salts, isomers, and salts
194 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
195 specific chemical designation:
196 (A) Mecloqualone; and
197 (B) Methaqualone.
198 (v) Any material, compound, mixture, or preparation containing any quantity of the
199 following substances having a stimulant effect on the central nervous system, including their
200 salts, isomers, and salts of isomers:
201 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
202 4,5-dihydro-5-phenyl-2-oxazolamine;
203 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
204 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
205 (C) Fenethylline;
206 (D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
207 alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
208 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
209 methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
210 optical isomers;
211 (E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
212 (F) N-ethylamphetamine; and
213 (G) N,N-dimethylamphetamine, also known as
214 N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
215 (vi) Any material, compound, mixture, or preparation which contains any quantity of
216 the following substances, including their optical isomers, salts, and salts of isomers, subject to
217 temporary emergency scheduling:
218 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
219 (B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
220 (vii) Unless specifically excepted or unless listed in another schedule, any material,
221 compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
222 (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
223 (b) Schedule II:
224 (i) Unless specifically excepted or unless listed in another schedule, any of the
225 following substances whether produced directly or indirectly by extraction from substances of
226 vegetable origin, or independently by means of chemical synthesis, or by a combination of
227 extraction and chemical synthesis:
228 (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
229 opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone,
230 and their respective salts, but including:
231 (I) Raw opium;
232 (II) Opium extracts;
233 (III) Opium fluid;
234 (IV) Powdered opium;
235 (V) Granulated opium;
236 (VI) Tincture of opium;
237 (VII) Codeine;
238 (VIII) Ethylmorphine;
239 (IX) Etorphine hydrochloride;
240 (X) Hydrocodone;
241 (XI) Hydromorphone;
242 (XII) Metopon;
243 (XIII) Morphine;
244 (XIV) Oxycodone;
245 (XV) Oxymorphone; and
246 (XVI) Thebaine;
247 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
248 identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
249 substances may not include the isoquinoline alkaloids of opium;
250 (C) Opium poppy and poppy straw;
251 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
252 any salt, compound, derivative, or preparation which is chemically equivalent or identical with
253 any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,
254 and salts of isomers and derivatives, whether derived from the coca plant or synthetically
255 produced, except the substances may not include decocainized coca leaves or extraction of coca
256 leaves, which extractions do not contain cocaine or ecgonine; and
257 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
258 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
259 (ii) Unless specifically excepted or unless listed in another schedule, any of the
260 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
261 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
262 chemical designation, except dextrorphan and levopropoxyphene:
263 (A) Alfentanil;
264 (B) Alphaprodine;
265 (C) Anileridine;
266 (D) Bezitramide;
267 (E) Bulk dextropropoxyphene (nondosage forms);
268 (F) Carfentanil;
269 (G) Dihydrocodeine;
270 (H) Diphenoxylate;
271 (I) Fentanyl;
272 (J) Isomethadone;
273 (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
274 levomethadyl acetate, or LAAM;
275 (L) Levomethorphan;
276 (M) Levorphanol;
277 (N) Metazocine;
278 (O) Methadone;
279 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
280 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
281 acid;
282 (R) Pethidine (meperidine);
283 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
284 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
285 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
286 (V) Phenazocine;
287 (W) Piminodine;
288 (X) Racemethorphan;
289 (Y) Racemorphan;
290 (Z) Remifentanil; and
291 (AA) Sufentanil.
292 (iii) Unless specifically excepted or unless listed in another schedule, any material,
293 compound, mixture, or preparation which contains any quantity of the following substances
294 having a stimulant effect on the central nervous system:
295 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
296 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
297 (C) Phenmetrazine and its salts; and
298 (D) Methylphenidate.
299 (iv) Unless specifically excepted or unless listed in another schedule, any material,
300 compound, mixture, or preparation which contains any quantity of the following substances
301 having a depressant effect on the central nervous system, including its salts, isomers, and salts
302 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
303 specific chemical designation:
304 (A) Amobarbital;
305 (B) Glutethimide;
306 (C) Pentobarbital;
307 (D) Phencyclidine;
308 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
309 1-piperidinocyclohexanecarbonitrile (PCC); and
310 (F) Secobarbital.
311 (v) (A) Unless specifically excepted or unless listed in another schedule, any material,
312 compound, mixture, or preparation which contains any quantity of Phenylacetone.
313 (B) Some of these substances may be known by trade or other names:
314 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
315 (vi) Nabilone, another name for nabilone:
316 (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
317 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
318 (c) Schedule III:
319 (i) Unless specifically excepted or unless listed in another schedule, any material,
320 compound, mixture, or preparation which contains any quantity of the following substances
321 having a stimulant effect on the central nervous system, including its salts, isomers whether
322 optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,
323 and salts of isomers is possible within the specific chemical designation:
324 (A) Those compounds, mixtures, or preparations in dosage unit form containing any
325 stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
326 listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
327 Code of Federal Regulations, and any other drug of the quantitive composition shown in that
328 list for those drugs or which is the same except that it contains a lesser quantity of controlled
329 substances;
330 (B) Benzphetamine;
331 (C) Chlorphentermine;
332 (D) Clortermine; and
333 (E) Phendimetrazine.
334 (ii) Unless specifically excepted or unless listed in another schedule, any material,
335 compound, mixture, or preparation which contains any quantity of the following substances
336 having a depressant effect on the central nervous system:
337 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
338 pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
339 which are not listed in any schedule;
340 (B) Any suppository dosage form containing amobarbital, secobarbital, or
341 pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
342 Administration for marketing only as a suppository;
343 (C) Any substance which contains any quantity of a derivative of barbituric acid or any
344 salt of any of them;
345 (D) Chlorhexadol;
346 (E) Buprenorphine;
347 (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
348 isomers, and salts of isomers, for which an application is approved under the federal Food,
349 Drug, and Cosmetic Act, Section 505;
350 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
351 ± -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
352 (H) Lysergic acid;
353 (I) Lysergic acid amide;
354 (J) Methyprylon;
355 (K) Sulfondiethylmethane;
356 (L) Sulfonethylmethane;
357 (M) Sulfonmethane; and
358 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
359 tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
360 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
361 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
362 flupyrazapon.
363 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
364 U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
365 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
366 (-)-delta-9-(trans)-tetrahydrocannabinol.
367 (iv) Nalorphine.
368 (v) Unless specifically excepted or unless listed in another schedule, any material,
369 compound, mixture, or preparation containing limited quantities of any of the following
370 narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
371 (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
372 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of
373 opium;
374 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
375 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
376 therapeutic amounts;
377 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
378 than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline
379 alkaloid of opium;
380 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
381 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
382 recognized therapeutic amounts;
383 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
384 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
385 therapeutic amounts;
386 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
387 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
388 recognized therapeutic amounts;
389 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
390 more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
391 recognized therapeutic amounts; and
392 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
393 one or more active, non-narcotic ingredients in recognized therapeutic amounts.
394 (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids
395 including any of the following or any isomer, ester, salt, or derivative of the following that
396 promotes muscle growth:
397 (A) Boldenone;
398 (B) Chlorotestosterone (4-chlortestosterone);
399 (C) Clostebol;
400 (D) Dehydrochlormethyltestosterone;
401 (E) Dihydrotestosterone (4-dihydrotestosterone);
402 (F) Drostanolone;
403 (G) Ethylestrenol;
404 (H) Fluoxymesterone;
405 (I) Formebulone (formebolone);
406 (J) Mesterolone;
407 (K) Methandienone;
408 (L) Methandranone;
409 (M) Methandriol;
410 (N) Methandrostenolone;
411 (O) Methenolone;
412 (P) Methyltestosterone;
413 (Q) Mibolerone;
414 (R) Nandrolone;
415 (S) Norethandrolone;
416 (T) Oxandrolone;
417 (U) Oxymesterone;
418 (V) Oxymetholone;
419 (W) Stanolone;
420 (X) Stanozolol;
421 (Y) Testolactone;
422 (Z) Testosterone; and
423 (AA) Trenbolone.
424 (vii) Anabolic steroids expressly intended for administration through implants to cattle
425 or other nonhuman species, and approved by the Secretary of Health and Human Services for
426 use, may not be classified as a controlled substance.
427 (d) Schedule IV:
428 (i) Unless specifically excepted or unless listed in another schedule, any material,
429 compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
430 less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.
431 (ii) Unless specifically excepted or unless listed in another schedule, any material,
432 compound, mixture, or preparation which contains any quantity of the following substances,
433 including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
434 salts of isomers is possible within the specific chemical designation:
435 (A) Alprazolam;
436 (B) Barbital;
437 (C) Bromazepam;
438 (D) Butorphanol;
439 (E) Camazepam;
440 (F) Carisoprodol;
441 (G) Chloral betaine;
442 (H) Chloral hydrate;
443 (I) Chlordiazepoxide;
444 (J) Clobazam;
445 (K) Clonazepam;
446 (L) Clorazepate;
447 (M) Clotiazepam;
448 (N) Cloxazolam;
449 (O) Delorazepam;
450 (P) Diazepam;
451 (Q) Dichloralphenazone;
452 (R) Estazolam;
453 (S) Ethchlorvynol;
454 (T) Ethinamate;
455 (U) Ethyl loflazepate;
456 (V) Fludiazepam;
457 (W) Flunitrazepam;
458 (X) Flurazepam;
459 (Y) Halazepam;
460 (Z) Haloxazolam;
461 (AA) Ketazolam;
462 (BB) Loprazolam;
463 (CC) Lorazepam;
464 (DD) Lormetazepam;
465 (EE) Mebutamate;
466 (FF) Medazepam;
467 (GG) Meprobamate;
468 (HH) Methohexital;
469 (II) Methylphenobarbital (mephobarbital);
470 (JJ) Midazolam;
471 (KK) Nimetazepam;
472 (LL) Nitrazepam;
473 (MM) Nordiazepam;
474 (NN) Oxazepam;
475 (OO) Oxazolam;
476 (PP) Paraldehyde;
477 (QQ) Pentazocine;
478 (RR) Petrichloral;
479 (SS) Phenobarbital;
480 (TT) Pinazepam;
481 (UU) Prazepam;
482 (VV) Quazepam;
483 (WW) Temazepam;
484 (XX) Tetrazepam;
485 (YY) Triazolam;
486 (ZZ) Zaleplon; and
487 (AAA) Zolpidem.
488 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
489 any quantity of the following substances, including its salts, isomers whether optical, position,
490 or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
491 isomers is possible.
492 (iv) Unless specifically excepted or unless listed in another schedule, any material,
493 compound, mixture, or preparation which contains any quantity of the following substances
494 having a stimulant effect on the central nervous system, including its salts, isomers whether
495 optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,
496 isomers, and salts of isomers is possible within the specific chemical designation:
497 (A) Cathine ((+)-norpseudoephedrine);
498 (B) Diethylpropion;
499 (C) Fencamfamine;
500 (D) Fenproprex;
501 (E) Mazindol;
502 (F) Mefenorex;
503 (G) Modafinil;
504 (H) Pemoline, including organometallic complexes and chelates thereof;
505 (I) Phentermine;
506 (J) Pipradrol;
507 (K) Sibutramine; and
508 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
509 (v) Unless specifically excepted or unless listed in another schedule, any material,
510 compound, mixture, or preparation which contains any quantity of dextropropoxyphene
511 (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
512 (e) Schedule V:
513 (i) Any compound, mixture, or preparation containing any of the following limited
514 quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid,
515 which includes one or more non-narcotic active medicinal ingredients in sufficient proportion
516 to confer upon the compound, mixture, or preparation valuable medicinal qualities other than
517 those possessed by the narcotic drug alone:
518 [
519 [
520 grams;
521 [
522 grams;
523 [
524 micrograms of atropine sulfate per dosage unit;
525 [
526 [
527 atropine sulfate per dosage unit;
528 [
529 schedule, any material, compound, mixture, or preparation which contains Pyrovalerone having
530 a stimulant effect on the central nervous system, including its salts, isomers, and salts of
531 isomers; and
532 [
533 (ii) Cannabidiol in a drug product that is approved by the United States Food and Drug
534 Administration.
Legislative Review Note
Office of Legislative Research and General Counsel